The Felbamate Study Group report results in 73 patients ages 4 to 36 years with the Lennox-Gastaut syndrome, using a double-blind, placebo- controlled, add-on trial design. A maximum dosage of 45 mg/kg/body wt or 3600 mg/day was titrated within 14 days. Felbamate-treated patients had a 34% decrease in frequency of atonic seizures, as compared with a 9% decrease in those receiving placebo. The total frequency of seizures was decreased by 19% in felbamate-treated patients, as compared with a 4% increase in the placebo group. Side-effects were similar in the two groups. Anorexia, vomiting, and somnolence occurred more frequently in the felbamate group, whereas diarrhea occurred more frequently in the placebo group. 
COMMENT. Felbamate (2-phenyl-l,3-propanediol dicarbamate) appears to be effective in the treatment of various types of seizures associated with the Lennox-Gastaut syndrome. Side effects are typically mild or moderate in severity and require no change in dosage. According to parental observations, the overall quality of life is also improved by increased alertness and verbal responsiveness.